Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
To the Editor Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of mature, post-thymic, T-and natural killer-cell non-Hodgkin lymphomas (NHL)-nearly all subtypes are associated with a poor prognosis.
1,2 Regardless of subtype, patients with PTCL typically receive induction chemotherapy (commonly CHOP[cyclophosphamide+doxorubicin+vincristine+predni-sone]) as first-line treatment. [3] [4] [5] Except for anaplastic lymphoma kinasepositive anaplastic large cell lymphoma, outcomes are generally poor and many responding patients rapidly relapse. [1] [2] [3] [4] Achievement of durable responses in patients with relapsed/refractory PTCL is difficult, and there arefew treatment options.
2-4
Angioimmunoblastic T-cell lymphoma (AITL) is a common subtype of PTCL (16% of diagnoses in the USA, 18% in Asia and 29% in Europe).
3
The 5-year overall survival (OS) in patients with AITL is reported to be just 32%, 3 and AITL is characterised by generalised lymphadenopathy, extranodal involvement, hypergammaglobulinemia, and advanced stage at presentation. 6, 7 Immune dysregulation commonly results in infections, which are a frequent cause of death in patients with AITL. 6 Romidepsin is a structurally unique, potent, bicyclic class I selective histone deacetylase inhibitor approved for the treatment of all subtypes of relapsed/refractory PTCL. [8] [9] [10] [11] In the pivotal phase 2 trial conducted in patients with relapsed/refractory PTCL, romidepsin treatment resulted in durable responses with manageable toxicity. 12, 13 The objective response rate (ORR) was 25%
(33/130), including 15% confirmed/unconfirmed complete responses (CR/CRu), 12, 13 and the median duration of response (DOR) was 28 months. 13 Patient baseline characteristics (including PTCL subtype) or prior treatments did not significantly affect response rates. 12, 13 The most frequent romidepsin-related adverse events (AEs)
were gastrointestinal and asthenic conditions, which were primarily grade 1/2 and rarely resulted in drug discontinuation. 12 Here, we report updated data from the pivotal phase 2 study focused on patients with AITL. In the overall study, eligible patients 15 were to be supplemented before romidepsin dosing.
Additional details for this open-label, single-arm, phase 2 study have been previously described. 12 The study was conducted in accordance with the Declaration of Response was assessed every two cycles by both investigators and an independent review committee (IRC; expert radiologists and hematologic oncologists) according to the 1999 IWG guidelines for NHL (IWG-NHL). 14 All descriptive statistical analyses were performed by using SAS statistical software version 9.2 (SAS Institute, Cary, NC, USA). Time-to-event data were summarised by Kaplan-Meier methods.
Of 131 total patients in the overall study, 27 were diagnosed with AITL. Largely, the baseline characteristics of the 27 patients with AITL (Table 1) were similar to those of the overall study population, which were previously reported. 12 Patients with AITL had higher-stage disease; only 4% of patients with AITL versus 29% of patients overall had stage I or II disease.
The ORR for patients with AITL treated with romidepsin was 33% Of the nine responding patients with AITL, five achieved a long-term response (≥12 months; Figure 1 ). Of these five patients, two had received one prior therapy, and three had received two prior therapies. The AE profile for patients with AITL was consistent with the known profile for romidepsin in patients with all subtypes of PTCL. 11- 13 The most common grade ≥3 AEs were thrombocytopenia (30%, all drug-related), neutropenia (22%, all drug-related), infections (all types pooled; 22%, 4% drug-related) and anemia (15%, 7% drug-related). Fifteen patients (56%) experienced serious AEs; nine (33%) of which were drug related. Infections (all types pooled) were the most common serious AE (n = 7, 26%), but no infection led to discontinuation. Overall, six patients (22%) discontinued due to AEs, including five (19%) for drug-related AEs. Doses were held or reduced because of AEs in 12 (44%) and five (19%) patients, respectively, including nine (33%) and five (19%) patients because of drug-related AEs. Thrombocytopenia was the most common AE leading to doses held or reduced in six (22%) and two (7%) patients, respectively, and the only AE that led to discontinuation in >1 patient (n = 2).
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